This drug has 5 hundred and twenty-eight patent member of the family in nineteen nations.
Kynamro is a drug marketed by Kastle Theraps Llc and is consisted of in one NDA. There are 4 patents safeguarding this drug.
The generic active ingredient in KYNAMRO is mipomersen sodium. Additional details are offered on the mipomersen salt profile page.
For more information on how DrugPatentWatch can aid with your pharmaceutical company intelligence needs, contact admin@DrugPatentWatch.com or check out www.DrugPatentWatch.com
DrugPatentWatch. Originally published at
New patent expiration for Kastle Theraps drug KYNAMROAnnual Drug Patent Expirations for KYNAMRO
Make Better Decisions with DrugPatentWatch
Get the Daily Briefing or Try a trial
DrugPatentWatch. Initially released at
New patent expiration for Kastle Theraps drug KYNAMRO